premise: Aerie's two lead product candidates are once-daily IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension.
hypothesis: Aerie 's two lead product candidates are once - daily IOP - lowering therapies with novel mechanisms of action to treat patients with ocular hypertension.